Billerica, MA, United States of America

Karl Hanf

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2010-2020

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Karl Hanf

Introduction

Karl Hanf is a notable inventor based in Billerica, MA (US), recognized for his contributions to the field of biotechnology. He holds a total of 4 patents, showcasing his innovative spirit and dedication to advancing medical science.

Latest Patents

Among his latest patents, Hanf has developed Anti-GPIIB/IIIA antibodies and their uses. These antibodies specifically bind to glycoprotein IIb/IIIa (GPIIb/IIIa) and include chimeric molecules that comprise such antibodies or antigen-binding fragments. The methods of using these antibodies, antibody fragments, and chimeric molecules are aimed at targeting agents to platelets and treating or preventing various diseases or disorders. Another significant patent is for Anti-CD154 antibodies, which provides peptides and fragments that include at least one amino acid substitution compared to the wild type 5c8 antibody. This invention also encompasses compositions and methods for treating CD154-related diseases or disorders in subjects.

Career Highlights

Hanf has worked with prominent companies in the biotechnology sector, including Biogen Idec MA Inc. and Biogen MA Inc. His work in these organizations has contributed to significant advancements in medical treatments and therapies.

Collaborations

Throughout his career, Hanf has collaborated with esteemed colleagues such as Alexey Alexandrovich Lugovskoy and Herman Van Vlijmen. These collaborations have further enriched his research and development efforts.

Conclusion

Karl Hanf's innovative contributions to biotechnology, particularly through his patents, highlight his role as a significant inventor in the field. His work continues to impact medical science and improve treatment options for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…